Equivalent Benefit of mTORC1 Blockade and Combined PI3K-mTOR Blockade in a Mouse Model of Tuberous Sclerosis

Molecular Cancer - United Kingdom
doi 10.1186/1476-4598-8-38
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Equivalent Benefit of Rapamycin and a Potent mTOR ATP-Competitive Inhibitor, MLN0128 (INK128), in a Mouse Model of Tuberous Sclerosis

Molecular Cancer Research
Cancer ResearchOncologyMolecular Biology
2013English

IL-1 Receptor Blockade Skews Inflammation Towards Th2 in a Mouse Model of Systemic Sclerosis

European Respiratory Journal
MedicinePulmonaryRespiratory Medicine
2019English

Survival Benefit and Phenotypic Improvement by Hamartin Gene Therapy in a Tuberous Sclerosis Mouse Brain Model

Neurobiology of Disease
Neurology
2015English

Analysis of a Mouse Skin Model of Tuberous Sclerosis Complex

PLoS ONE
Multidisciplinary
2016English

Rapamycin Prevents Epilepsy in a Mouse Model of Tuberous Sclerosis Complex

Annals of Neurology
Neurology
2008English

Estrogen Receptor Β Ligand Therapy Activates PI3K/Akt/mTOR Signaling in Oligodendrocytes and Promotes Remyelination in a Mouse Model of Multiple Sclerosis

Neurobiology of Disease
Neurology
2013English

Dissociation of the Pharmacological Effects of THC by mTOR Blockade

Neuropsychopharmacology
PsychiatryMental HealthPharmacology
2013English

Preclinical Testing of PI3K/AKT/mTOR Signaling Inhibitors in a Mouse Model of Ovarian Endometrioid Adenocarcinoma

Clinical Cancer Research
Cancer ResearchOncology
2011English

Blockade of Gap Junction Hemichannel Suppresses Disease Progression in Mouse Models of Amyotrophic Lateral Sclerosis and Alzheimer's Disease

PLoS ONE
Multidisciplinary
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy